START Midwest team has dosed the first patient in the Loxo Lilly study – The START Center for Cancer Research
shared a post on Linkedin:
“We are thrilled to announce that our START Midwest team has dosed the first patient in the Loxo Lilly study, LOXO-LNC-2400.
This Phase 1a/1b multicenter, open-label study aims to evaluate the safety, tolerability, and effectiveness of the study drug, LY4052031, an antibody-drug conjugate (ADC), in participants with advanced or metastatic solid tumors known to express Nectin-4, including urothelial cancer.
The study is being conducted in two parts: Dose-escalation and dose-optimization (1a), and dose-expansion (1b). It is also an open trial at our San Antonio site.
This achievement marks a significant step forward in our commitment to advancing innovative cancer treatments. We are proud of our team’s dedication and the collaboration with Loxo Lilly in bringing hope to patients worldwide.”
Source: /Linkedin